Summary of results of PETIT and PETIT2
| . | PETIT . | PETIT2 . | ||
|---|---|---|---|---|
| Eltrombopag, % . | Placebo, % . | Eltrombopag, % . | Placebo, % . | |
| Platelet response* | 62 | 32 | 75 | 21 |
| Sustained response† | 36 | 0 | 41 | 3 |
| Required rescue therapy | 13 | 50 | 19 | 24 |
| Able to discontinue or decrease concomitant therapies‡ | 23 | — | 46 | — |
| Clinically significant grade 2-4 bleeding | 9 | 32 | 5 | 7 |
| . | PETIT . | PETIT2 . | ||
|---|---|---|---|---|
| Eltrombopag, % . | Placebo, % . | Eltrombopag, % . | Placebo, % . | |
| Platelet response* | 62 | 32 | 75 | 21 |
| Sustained response† | 36 | 0 | 41 | 3 |
| Required rescue therapy | 13 | 50 | 19 | 24 |
| Able to discontinue or decrease concomitant therapies‡ | 23 | — | 46 | — |
| Clinically significant grade 2-4 bleeding | 9 | 32 | 5 | 7 |
PETIT and PETIT2 demonstrated a rise in platelet count, sustained platelet increases, decreased need for other therapies, and reduced bleeding with use of eltrombopag.
Platelet count of ≥50 × 109/L without rescue therapy during days 8 to 43 in PETIT and during weeks 1 to 12 in PETIT2.
Platelet count of ≥50 × 109/L without rescue therapy in ≥60% of assessments during weeks 2 to 6 in PETIT and for ≥6 weeks during weeks 5 to 12 of PETIT2.
Eltrombopag only phase (no placebo arm).